The purpose of the study is to evaluate the effectiveness and safety of Bepirovirsen in achieving a functional cure for individuals with chronic hepatitis B who are already being treated with nucleos(t)ide analogues, a type of medication that helps control the virus. The study will last for 24 weeks, during which participants will receive Bepirovirsen with initial higher doses to help achieve the desired treatment effect. The goal is to see if Bepirovirsen can help reduce the virus to very low levels or eliminate it altogether, allowing participants to stop their current hepatitis B treatment.

Throughout the study, participants will be closely monitored to ensure their safety and to assess how well the treatment is working. The study aims to provide valuable information on whether Bepirovirsen can be an effective treatment option for people with chronic hepatitis B, potentially leading to a new way to manage this condition.

The purpose of this study is to evaluate how well the combination of Tobevibart and Elebsiran works compared to Bulevirtide in reducing the amount of virus in the body and to assess the safety of these treatments. Participants in the study will receive either the combination therapy or Bulevirtide and will be monitored over a period of time to see how their condition changes. The study will also look at how the treatments affect the liver and overall health of the participants.

Participants will receive the treatments through subcutaneous injections, which means the medication is injected under the skin. The study will take place over several weeks, with regular check-ups to monitor the participants’ health and the effectiveness of the treatments. The goal is to find out which treatment is more effective in managing Chronic Hepatitis D Virus (HDV) Infection and to ensure that the treatments are safe for the participants.

The purpose of the study is to evaluate how well the combination of Tobevibart and Elebsiran works in reducing the virus in the body. Participants in the study will receive these treatments through injections under the skin. The study will be conducted over a period of time, with regular check-ups to monitor the effects of the treatment. The study will also look at how the treatment affects liver health and any side effects that may occur.

Participants will be monitored for changes in their health, including the amount of virus in their blood and the condition of their liver. The study aims to provide valuable information on the effectiveness and safety of the combination therapy for people with Chronic Hepatitis D Virus Infection who have not responded well to previous treatments.

Participants in the study will receive Pomalidomide in the form of a capsule taken orally. The study will monitor the safety of the medication by observing any side effects that may occur during the treatment. Additionally, the study will assess various aspects of the participants’ health, such as the levels of the virus in the blood, liver function, and the activity of certain immune cells. These assessments will help researchers understand how Pomalidomide affects the body and its potential benefits for people with chronic hepatitis B.

The study is expected to take place over several years, with an estimated completion date in 2026. Participants will be closely monitored throughout the study to ensure their safety and to gather important data on the effects of Pomalidomide. This research aims to provide valuable insights into new treatment options for individuals living with chronic hepatitis B.

The purpose of this study is to assess how effective and safe the combination of Tobevibart and Elebsiran is for people with chronic HDV infection. Participants in the study will receive these medications through injections under the skin. The study will compare the effects of starting the treatment immediately versus delaying it. Throughout the study, participants will have regular check-ups to monitor their health and the virus’s response to the treatment.

The study will last for several years, with participants being observed at different intervals to see how the treatment affects the virus and their liver health over time. The goal is to see if the combination of Tobevibart and Elebsiran can reduce the amount of virus in the body and improve liver function. Participants will be closely monitored for any side effects or changes in their condition during the study period.

The purpose of the study is to assess the treatment effect of Bepirovirsen over a period of 24 weeks, with the goal of achieving a response in the Hepatitis B Virus 36 weeks after stopping the study treatment. Participants in the study will continue their regular antiretroviral treatment for HIV while receiving the study medication. The study will involve regular visits to monitor the health and progress of the participants, ensuring that the treatment is working as intended and that there are no significant side effects.

Participants will be randomly assigned to receive either Bepirovirsen or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The study aims to determine the percentage of participants who achieve undetectable levels of the Hepatitis B surface antigen (HBsAg) and HBV DNA, which are indicators of the virus’s presence in the body, 36 weeks after the end of the study treatment. The study will help to understand if Bepirovirsen can be an effective treatment option for those living with both HIV and chronic HBV infection.

The purpose of the study is to assess how effective and safe these treatments are for people with chronic HDV infection. Participants will receive the treatments through injections under the skin. The study will monitor the participants over a period of time to observe any changes in their health and to check for any side effects. The study aims to see if the treatments can reduce the amount of virus in the body and improve liver function.

Throughout the study, participants will have regular check-ups to track their progress. The study will look at how the treatments affect the virus levels and liver health at different points in time. This research is important for understanding how these new therapies might help people with chronic HDV infection in the future.

The purpose of the study is to evaluate the effectiveness and safety of the treatment combination. Participants in the study will receive either the new treatment with the nucleos(t)ide analog or a placebo. The study will be conducted over a period of time, during which participants will be monitored for changes in their health and the levels of the viruses in their bodies. The study aims to see if the combination treatment can reduce the amount of the Hepatitis D virus in the body and improve liver health.

Throughout the study, participants will have regular check-ups and tests to track their progress. The study is designed to provide valuable information about the potential benefits of the new treatment for people with these viral infections. The results will help determine if this combination of medications can be a safe and effective option for managing Hepatitis B and Hepatitis D co-infections.

The purpose of the study is to evaluate the safety and effectiveness of these vaccines in adults aged 18 to 65 who have Chronic Hepatitis B and are already receiving treatment with medications called nucleos(t)ide analogues, which help control the virus. Participants will receive the vaccines through injections into the muscle, and the study will monitor how their bodies react to the vaccines over time. Some participants may receive a placebo, which is a substance with no active ingredients, to compare the effects of the vaccines.

Throughout the study, participants will have regular check-ups to assess their health and the vaccines’ impact on their immune system. The study will look at how well the vaccines help the body produce antibodies, which are proteins that fight infections, and how they affect specific immune cells. The study will also track any side effects or health changes that occur after receiving the vaccines. The trial is expected to continue until October 2025, providing valuable information on the potential benefits and safety of these new vaccines for people with Chronic Hepatitis B.

The purpose of the study is to evaluate the safety and effectiveness of this sequential treatment in patients with Chronic Hepatitis B who are stable on their current therapy. Participants will be randomly assigned to receive either the new treatment or a placebo. The study will monitor how well the treatment works in reducing the virus and improving the immune response, as well as any side effects that may occur. The treatment will be administered through injections, with GSK3228836 given subcutaneously (under the skin) and GSK3528869A given intramuscularly (into the muscle).

Throughout the study, participants will have regular check-ups to assess their health and the treatment’s impact on the virus. The study aims to provide valuable information on whether this new treatment approach can offer a better way to manage Chronic Hepatitis B and improve patient outcomes. The trial is expected to continue until early 2026, allowing researchers to gather comprehensive data on the treatment’s long-term effects.